Verona Pharma plc (VRNA) ADR Each Representing 8 Ord Shares SPON

Sell:$67.00Buy:$68.95$3.77 (5.87%)

Prices delayed by at least 15 minutes
Sell:$67.00
Buy:$68.95
Change:$3.77 (5.87%)
Deal now
Prices delayed by at least 15 minutes
Sell:$67.00
Buy:$68.95
Change:$3.77 (5.87%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Key people

David S. Zaccardelli
President, Chief Executive Officer, Executive Director
Mark W. Hahn
Chief Financial Officer
Claire Louise Poll
General Counsel
Kathleen Rickard
Chief Medical Officer
Ben Harber
Company Secretary
David Raymond Ebsworth
Non-Executive Independent Chairman of the Board
Christina Ackermann
Non-Executive Director
Michael Austwick
Non-Executive Director
James Brady
Non-Executive Independent Director
Kenneth D. Cunningham
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US9250501064
  • Market cap
    $5.24bn
  • Employees
    79
  • Shares in issue
    667.66m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.